OTTAWA, Oct. 31 /CNW Telbec/ - PharmaGap Inc. (TSX-V: GAP) ("PharmaGap"
or "the Company"), a Canadian biotechnology company, today announced that it
has entered into an agreement with Memorial Sloan-Kettering Cancer Center
("Sloan-Kettering"). Sloan-Kettering researchers, led by Dr. Gary K. Schwartz,
will study PharmaGap's novel preclinical cancer drug, PhGalpha1, in a series
of collaborative in vitro and in vivo (animal) studies to assess its efficacy
and potency as a specific inhibitor of protein kinase C alpha ("PKCalpha").
PKCalpha, which is a major component of cellular signal transduction pathways,
is expressed in many types of tumors, including colorectal cancer, non-small
cell lung cancer, breast cancer and certain gastric cancers and therefore
represents a new target for cancer therapy.
